Clinical trial / 2018
In patients with diabetes, daily n-3 fatty acid supplementation did not reduce the risk of serious vascular events over 7.4 years of follow-up.
Researchers randomly assigned 15,480 patients with diabetes and no evidence of atherosclerotic cardiovascular disease to receive daily 1-g capsules of n-3 fatty acids or an olive oil placebo. Over a mean follow-up of 7.4 years, serious vascular events occurred in 8.9% of the fatty acid group and 9.2% of the placebo group (rate ratio, 0.97; 95% CI, 0.87 to 1.08; P=0.55). The composite outcome of a serious vascular event or revascularization occurred in 11.4% and 11.5%, respectively (rate ratio, 1.00; 95% CI, 0.91 to 1.09), and all-cause death occurred in 9.7% versus 10.2% (rate ratio, 0.95; 95% CI, 0.86 to 1.05).
- Study type
- Randomized, placebo-controlled trial
- Who was studied
- 15,480 patients with diabetes without evidence of atherosclerotic cardiovascular disease
- What was measured
- First serious vascular event; secondary outcome was first serious vascular event or any arterial revascularization
THE PAPER
Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus.
ASCEND Study Collaborative Group, Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G, Barton J, Murphy K, Aung T, Haynes R, Cox J, Murawska A, Young A, Lay M, Chen F, Sammons E, Waters E, Adler A, Bodansky J, Farmer A, McPherson R, Neil A, Simpson D, Peto R, Baigent C, Collins R, Parish S, Armitage J. N Engl J Med, 2018.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.